Home > PE Ratio > BETA DRUGS

BETA DRUGS
PE (Price/Earnings) Ratio

The Current P/E Ratio of BETA DRUGS is 37.86.

Share Price ₹1,819.0Nov 08,2026
Market Cap ₹2,019.1 Cr
Earnings-TTM₹53.3 CrTTM-Consolidated Results
Price/Earnings37.86xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for BETA DRUGS
Please provide your vote to see the results
BETA DRUGS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of BETA DRUGS

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of BETA DRUGS is calculated as :

Current Market Cap [ ₹2,019.1 Cr] as on Nov 08,2026

(/) Earnings [ ₹53.3 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 37.86x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for BETA DRUGS , the investors are currently willing to pay 37.86 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BETA DRUGS !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of BETA DRUGS over the last five years.

Historical PE (Price/Earnings) ratio chart of BETA DRUGS


PE Ratio Performance Analysis for BETA DRUGS

- BETA DRUGS 's latest p/e ratio is 37.86x.

- BETA DRUGS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 29.36x.

- BETA DRUGS 's operated at median p/e ratio of 28.94x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, BETA DRUGS 's p/e ratio peaked in Mar2025 at 45.35x.

- BETA DRUGS 's p/e ratio hit its five-year low in Mar2023 of 19.62x.


How does BETA DRUGS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
BETA DRUGS 53.3437.862,019.1
SUN PHARMACEUTICAL INDUSTRIES LTD11,037.2041.63459,497.0
DIVIS LABORATORIES LTD3,363.0087.47294,146.0
TORRENT PHARMACEUTICALS LTD2,099.0086.46181,474.0
CIPLA LTD2,868.2939.74113,989.0
DR REDDYS LABORATORIES LTD2,759.7041.44114,349.0
MANKIND PHARMA LTD2,249.6947.32106,446.0
LUPIN LTD5,221.4717.4791,230.0
ZYDUS LIFESCIENCES LTD4,159.0028.78119,700.0
AUROBINDO PHARMA LTD3,993.0526.02103,913.0
LAURUS LABS LTD1,333.7596.01128,054.0

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BETA DRUGS 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 17.47x
Max industry PE 96.01x
Median industry PE 41.44x
Average industry PE 50.02x



You may also like the below Video Courses